Published in:
01-08-2012 | Letter
Impact of nystatin on Candida and the oral microbiome
Authors:
Christopher D Hingston, Emma J Hingston, Matt P Wise
Published in:
Critical Care
|
Issue 4/2012
Login to get access
Excerpt
In a recent issue of
Critical Care, Giglio and colleagues [
1] reported that oral nystatin reduced
Candida colonization in a cohort of critically ill surgical patients, even when colonization was present at baseline. Colonization is a prerequisite for systemic infection, which is associated with significant morbidity and mortality. Although it is possible to stratify individuals at risk of invasive fungal disease, diagnosing this condition is complex, and the present study [
1] represents a potential mechanism for reducing the burden of fungal infection.
Candida albicans has a complicated relationship with potential bacterial respiratory pathogens and augments their growth in mixed biofilms [
2,
3].
Pseudomonas aeruginosa is unable to bind yeast forms of
C. albicans but forms a dense biofilm on
C. albicans filaments [
3]. This is relevant to clinical investigations in which respiratory tract colonization with
C. albicans is associated with an increased risk of
Pseudomonas ventilator-associated pneumonia (VAP) [
4], which is reduced with antifungal treatment [
5]. One impact of nystatin on other infections, such as VAP caused by
Pseudomonas or
Staphylococcus, or indeed on other indices, such as length of stay and mortality, was not measured [
1]. One might anticipate that the benefit of nystatin treatment will extend beyond infections caused directly by
Candida, but there is an important caveat. Nystatin generally is used as a suspension with high sucrose content (49.8% wt/vol), and growth of oral plaque is driven by sugars. Dental plaque becomes colonized with potential respiratory pathogens in critically ill patients and is important in the etiology of VAP. Future studies, therefore, should investigate the impact of nystatin on the oral microbiome, VAP, and mortality. …